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Objective:  We  aimed  to explore  the  impacts  of  new  vaccine  introductions  on  immunization  programmes
and  health  systems  in  low-  and  middle-income  countries.
Methods: We  conducted  case  studies  of seven  vaccine  introductions  in six  countries  (Cameroon,  PCV;
Ethiopia,  PCV;  Guatemala,  rotavirus;  Kenya,  PCV;  Mali,  Meningitis  A;  Mali,  PCV; Rwanda,  HPV).  Inter-
views  were  conducted  with  261  national,  regional  and  district  key informants  and  questionnaires  were
completed  with  staff  from  196  health  facilities.  Routine  data  from  districts  and  health  facilities  were
gathered  on  vaccination  and  antenatal  service  use.  Data  collection  and  analysis  were  structured  around
the  World  Health  Organisation  health  system  building  blocks.
Findings: The  new  vaccines  were  viewed  positively  and  seemed  to integrate  well into  existing  health
systems.  The  introductions  were  found  to  have  had  no  impact  on  many  elements  within  the  building
blocks  framework.  Despite  many  key  informants  and  facility  respondents  perceiving  that  the  new  vaccine
introductions  had  increased  coverage  of  other  vaccines,  the routine  data  showed  no  change.  Positive
effects  perceived  included  enhanced  credibility  of the  immunisation  programme  and  strengthened  health
workers’  skills  through  training.  Negative  effects  reported  included  an  increase  in workload  and  stock
outs  of the  new  vaccine,  which  created  a perception  in  the  community  that  all vaccines  were  out  of  stock
in  a facility.  Most  effects  were  found  within  the  vaccination  programmes;  very  few  were  reported  on  the
broader  health  systems.  Effects  were  primarily  reported  to  be  temporary,  around  the  time  of  introduction
only.
Conclusion:  Although  the  new  vaccine  introductions  were  viewed  as  intrinsically  positive,  on  the  whole
there  was  no  evidence  that they  had  any  major  impact,  positive  or negative,  on  the  broader  health  systems.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND∗ Corresponding author at: 15-17 Tavistock Place, London, WC1H 9SH, UK.
el.:  +44 (0)20 7927 2700.
E-mail  address: helen.burchett@lshtm.ac.uk (H.E.D. Burchett).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.031
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. IntroductionThe pace of new vaccine introductions in low- and middle-
income countries has been accelerating in the past decade and
will continue [1]. This has led to increased attention on their
broader impact, with the possibility that they may either stress or
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
Details of the vaccine introductions studied.
Country Vaccine studied Date of
introduction
Data collection period Vaccine introduction process
Cameroon PCV13 July 2011 May–June 2012 GAVI funded
Planned for PCV7 in 2010
Switched  to PCV13 when it became available, but
supply issues delayed its introduction
Ethiopia PCV10 November 2011 December
2012–January 2013
GAVI  funded
Catch up for <1 year olds
Guatemala Rotavirus February 2010 July 2011 Government funded
Only  limited introduction preparations; no
introduction plan prepared
Initially  introduced Rotateq (two doses), then switched
to  Rotarix (three doses), then back to Rotateq
Rotateq not purchased through PAHO revolving fund
No  national social mobilisation
Kenya PCV10 February 2011 July–August 2011
and
March–April 2012
GAVI  funded.
First  sub-Saharan African GAVI country to introduce
PCV
Catch up for <1 year olds
Mali Men  A September
2010–December
2011
July–August 2011
and  January 2012
GAVI  funded
Introduction over three phases
10 days campaign, targeting
1–29  year olds
Key  role of WHO
MSF  implemented in a few districts
Mali PCV13 March–December
2011
March–June 2011 and
January  2012
GAVI funded
Nationwide introduction phased over 10+ months
Rwanda HPV April 2011 August 2012 3 year donation from Merck
First  African country to introduce HPV
Vaccination through school-based 2-day campaign for
girls  in 6th year of primary school. Some catch up in
other  grades during second and third year of
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itrengthen health systems in these countries. In 2010, the World
ealth Organization (WHO) set up an ad-hoc working group to
xplore the issue for their Strategic Advisory Group of Experts on
mmunisation [1]. Members of the team for the present study par-
icipated in this group and our preliminary results informed the
roup’s ﬁndings and recommendations [2].
There is a lack of research focusing on the impact of new vaccine
ntroductions on countries’ expanded programme of immunisa-
ion (EPI) or health system as a whole, particularly in low-income
ountries [3,4]. Previous research has typically focused either on
he impact of vaccination campaigns on the routine immunisation
ervice [5–8], or the impact of new vaccine introductions on spe-
iﬁc elements of the health system, such as cold chain [9], logistics
nd supply [10,11] or coverage [12].
The EPI is traditionally a relatively vertical programme, although
outine immunisation is arguably more integrated than vaccination
ampaigns. Research on the health system impact of other vertical
ealth programmes, including vaccination campaigns, have iden-
iﬁed both positive and negative effects [6,13–16]. It has also been
oted that these impacts varied depending on the strength of the
ealth system [6,15].
This  study aimed to explore impact of new vaccine introductions
n immunisation programmes and the broader health system. It did
ot aim to estimate the costs of new vaccine introductions as this
ould require a different type of methodology and has been the
ocus of another multi-country research project.. Methods
We  conducted mixed-method case studies of seven vaccine
ntroductions in six low- and middle-income countries (see Table 1campaigns. For girls not at school, 12 year olds were
targeted at the nearest health centres
Campaign ran three times per year
for details). The study team comprised staff from The London School
of Hygiene and Tropical Medicine (LSHTM), as well as at least one
collaborator per case study country. Data collection was  conducted
by both the country collaborators and LSHTM staff.
2.1.  Case studies sampling frame
Countries were selected to include a range of vaccines, presen-
tations, delivery strategies and ﬁnancing mechanisms. Countries
were eligible for inclusion if they planned to introduce a new vac-
cine in 2010 or 2011, in order for this introduction to be sufﬁciently
recent at the time of data collection. Five of the seven vaccine intro-
ductions were funded by the GAVI Alliance; rotavirus in Guatemala
and human papilloma virus (HPV) in Rwanda were the excep-
tions. In Mali and Rwanda, Meningitis A (Men A) and HPV vaccines
were introduced respectively using a campaign-based approach.
In Mali, the introduction was through a mass catch-up campaign
organised in three separate phases and in Rwanda through a school-
based delivery model that was part of the national immunisation
schedule. In the remaining countries the new vaccines, pneumococ-
cal vaccine (PCV) and rotavirus, were introduced into the routine,
infant immunisation programme.
2.2. Within-country sampling
Within  countries, two to four regions were selected based on
their vaccination coverage (high, average and low compared to
national ﬁgures). Two to three districts were selected purposively
within each region, representing different vaccination coverage
rates as well as both urban and rural areas.
H.E.D. Burchett et al. / Vaccine
Table  2
Number of regions, districts and facilities included in study, per country.
Country Regions Total districts
(Districts per region)
Total facilities
(Facilities per district)
Cameroon 3 9
(3)
28
(3–4)
Ethiopia 4 10
(1–3)
26
(1–3)
Guatemala 3 9
(3)
27
(3)
Kenya 3 9
(3)
43
(4–5)
Mali (Men A) 2 6
(3)
18
(3)
Mali (PCV) 3 9
(3)
27
(3)
a
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SRwanda 3 9
(3)
27
(3)
One to ﬁve health facilities were selected per district, based on
n increasing distance from the main urban centre and to include
 range of provider types (Table 2).
.3. Data collection
Three  methods of data collection were used:
. Semi-structured interviews with key informants selected at
national,  regional and district levels.
.  Structured questionnaire with health facility staff.
. Collection of routine vaccination and antenatal care (ANC)
service  use data.
The qualitative data collection and analysis were framed by an
dapted version of the WHO  health system building blocks (see
able 3) [17].
Semi-structured interviews at the national level were con-
ucted with key informants from the Ministry of Health and
takeholders from other relevant organisations (e.g. WHO, UNICEF,
able 3
tudy  analysis framework.
Health system building
block
Vaccination-speciﬁc component
Service delivery  Access and utilisation
  Delivery modalities
  Demand and acceptance
Health workforce  Availability and distribution of staff
 Training and capacity of staff
 Remuneration and satisfaction
 Performance and supervision
Health information
system
  Routine data collection and reporting
 Disease surveillance
Medical products,
vaccines and
technologies
  Forecasting and procurement of vaccines
and injection supplies
  Stock management
  Cold chain management and waste disposal
Financing and
sustainability
  Affordability
 Domestic ﬁnancing
  External ﬁnancing
Leadership/governance  Regulatory policy
  Political commitment
  Organisation, structure, reform, negotiation,
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Inter-agency Coordinating Committee members and, in Rwanda,
teachers). Regional- and district-level health service managers and
staff specialised in immunisation or logistics management were
also interviewed. The interviews included questions on the health
system building block components detailed in Table 3; where inter-
viewees’ roles were more specialised, questions focused on their
areas of expertise. Interviews were recorded when permitted and
possible. All those recorded were transcribed and, when necessary,
translated. Notes were made of interviews not recorded.
A  researcher-administered questionnaire was  completed with
one staff member in each facility. Questions were adapted from the
WHO’s post-introduction evaluation (PIE) tool and were structured
around the study framework (Table 3) [18].
Data were gathered on coverage of the new vaccine and the
diphtheria, tetanus, pertussis (DTP) as well as ANC service use,
from routine service use records held in facilities and/or districts.
Monthly data were collected for 1 year before and after the new vac-
cine was introduced in that facility/district (only 5 and 10 months
afterwards in Kenya and Cameroon, respectively, due to the tim-
ing of data collection). In Rwanda and Mali (for Men  A), data were
collected 1 month before, during and after the campaign.
2.4.  Analysis
Thematic content analysis was used to explore the interview
data within Open Code software [19]. Two  investigators led the
cross-country analysis of the transcripts and ﬁndings were checked
with other members of the LSHTM study team and the in-country
researchers. The study’s framework was  used to structure this
analysis (see Table 3). Questionnaire responses were cleaned and
re-coded to allow comparison across countries, where necessary
and possible. They were then analysed using descriptive statistics
in SPSS software. Routine data were plotted over time and if a small
change in trend was visible, a segmented regression analysis was
conducted to formally test its statistical signiﬁcance [20].
2.5.  Ethics
Ethical approval was  gained from the London School of Hygiene
and Tropical Medicine and from the study countries. The study was
verbally described to participants, an information sheet was pro-
vided and signed consent gained from all, prior to commencing data
collection.
3. Results
261 semi-structured interviews were conducted and 196 health
facility questionnaires were completed (see Table 4). 245 inter-
views were recorded (94%) and 65 interviews were translated from
Spanish, Amharic and Kinyarwanda into English.
The new vaccines generally seemed to integrate well into exist-
ing health systems. The introductions were considered to have had
no impact on many of the elements within the building blocks
framework (see Table 5 for summary of ﬁndings). Of those effects
that were identiﬁed, most were within the vaccination programme;
very few effects on the broader health system were reported. Some
effects (e.g. increased staff workload) were reported to be tempo-
rary, at the time of introduction only. Given space limitations, only
key ﬁndings are discussed below.
3.1. No effect3.1.1.  Access and utilisation
Despite  many key informants and facility respondents perceiv-
ing that the new vaccine introductions had increased coverage of
other vaccines, especially in Kenya, Cameroon and Ethiopia, the
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Table 4
Data  collected in each case study.
Country National
interviewees
Regional
interviewees
District interviewees Total number of
interviewees
Number
recorded
Number
translated
Facility
questionnaires
Cameroon 10 14 23 47 45 None. Interviews and analysis
conducted  by French and
English  speakers
28
Ethiopia 8 4 11 23 21 13 translated from Amharic, 10
conducted in English
26
Guatemala 11 15 16 42 42 All translated from Spanish 27
Kenya 14 11 26 51 49 None. All interviews conducted
in  English
43
Mali (Men A) 19 3 9 31 29 None. Interviews and analysis
conducted  by French speakers
18
Mali (PCV) 1* 8 28 37 31 None. Interview and analysis
conducted  by French speakers
27
Rwanda 12 n/a 11 (+7 school
employees)
30 28 10 translated from
Kinyarwanda into English
27
261
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* 15 national interviews in Mali discussed both Men  A and PCV13 introduction –
outine data collected in all countries did not support these claims
see Fig. 1). The only exception was in the case of Mali (PCV), where
ptake of the ﬁrst pentavalent dose increased by about 40% (Fig. 1),
lthough this effect was not sustained over time. However it should
lso be noted that the analysis in Mali (PCV) was based on data from
nly 13 of the 27 included facilities, due to incomplete data being
vailable in the remaining 14 facilities.
The high demand for new vaccines may  have encouraged those
ho had previously defaulted on existing routine vaccinations. This
reated an opportunity to check the vaccine status of those attend-
ng and, when necessary, administer missed doses. Although study
articipants reported isolated efforts to use the new vaccine to trace
efaulters in this manner, no country demonstrated a systemic
pproach to this.
No  impact of the introduction on ANC service use was observed
rom routine data before and after the introductions.
.1.2. Cold chain
Study  participants generally felt that the new vaccine introduc-
ions had not affected cold chain capacity for other vaccines or
roducts, for a number of reasons. Cold chain assessments had been
onducted as part of the planning processes (for GAVI countries,
t is required as part of the application process). In some cases,
uch as in Rwanda, no expansion was deemed necessary. In other
ountries national-level interviewees reported that there had been
n expansion or modernisation of the cold chain in preparation for
he introduction, although this was generally at the national and
ub-national levels, rather than in facilities.
There was a discrepancy between some national- and facility-
evel responses, with the former reporting cold chain expansion
hilst the latter reported none. It is not clear whether this dis-
repancy was because expected expansions had not occurred, or
hether facility staff had not realised that new equipment received
sometimes up to a year earlier) was for a particular vaccine intro-
uction.
In four countries, the presentation of other vaccines had changed
pentavalent in Cameroon, Kenya and Mali, and PCV in Rwanda),
hich reduced their cold chain requirement, making capacity avail-
ble for the new vaccine. Finally, some districts and a minority of
acilities reported using adaptive strategies, such as more frequent
accine deliveries, in order to manage their cold chain space.
“There is a problem with the cold chain because the volume
[of  vaccines] is bigger and districts are struggling with the cold 245 (94%) 65 196
 have been included under ‘Mali Men  A’.
chain. . . there is no space. They [the health centres] have to take
small  quantities; we send them the remainder when there is an
opportunity. This creates a risk of stock outs. . .”
C 05, regional-level interviewee, Cameroon
Guatemala was an exception in that no assessment was
conducted before the introduction and there was no nationally-
organised cold chain expansion. Some equipment was reported
to have been procured at sub-national levels after the introduc-
tion.
3.1.3. Regulatory policy
Interviewees  in most countries reported no effect on regula-
tory policies, with some exceptions. In Kenya, WHO  worked to
strengthen the country’s Pharmacy and Poisons Board in order
to register the new vaccine. It was  felt that this would be bene-
ﬁcial for future vaccines. In Mali, the national regulatory process
was bypassed for both Men  A and PCV vaccines. In doing so, some
interviewees argued that this weakened national ownership and
domestic regulatory processes.
3.1.4. Organisation, structure, reform, negotiation and
stewardship: Inter-agency Coordinating Committees (ICCs)
In  most countries the new vaccines were not thought to have
affected the functioning of their ICCs. However, in Mali (for Men
A) and in Rwanda, membership of the committees was extended
to additional stakeholders. In Ethiopia some interviewees felt that
the ICC had been strengthened by the introduction, particularly
because of highly active thematic sub-committees.
3.1.5. Demand/acceptance
Vaccination is, in general, well accepted and this was the case for
the new vaccines too, with high acceptance and demand reported.
Only a minority of facilities reported that they had experienced
any resistance from the community regarding the new vaccine –
this was most common in Rwanda for the HPV vaccine, or because
of a fear of the effect of receiving two  vaccinations at once (e.g. in
Ethiopia, where PCV and pentavalent were given at the same time).
Study participants did not feel that the new vaccines had affected
the acceptance of other vaccines, perhaps due to the fact that they
were already well accepted.
H.E.D. Burchett et al. / Vaccine 32 (2014) 6505–6512 6509
Table  5
Impact of new vaccine introductions by health system building block components.
Health system
building block
Vaccination-speciﬁc
component
No impact on: Positive  impact on: Negative impact on:
Service delivery Access and utilisation Other vaccines’ coverage rates
Health service use
Delivery modalities Delivery modalities
Co-delivery of interventions alongside
vaccination (except Rwanda, positive impact)
Demand and acceptance Acceptance of other vaccines Trust and credibility of EPI
enhanced
Health workforce Availability and distribution of
staff
Stafﬁng numbers or distribution (except for
campaign-based introductions)
Workload increased in
the  short term
Training and capacity of staff Skills strengthened
through training
Remuneration and satisfaction Remuneration (except for campaign-based
introductions)
Staff morale boosted
Performance and supervision Supervision
Health information
system
Routine data collection and
reporting
Information systems
Surveillance Disease surveillance Awareness of adverse
events  following
immunisation (AEFIs)
increased  (although no
effect  on reporting)
Strengthening of AEFI
surveillance  systems
(Ethiopia,  Mali)
Medical products,
vaccines and
technologies
Forecasting and procurement
of  vaccines and injection
supplies
Forecasting/procurement
Stock management Stock management
Wastage rates
Stock  outs of new
vaccine  – creating a
perception  that all
vaccines  were out of
stock  in the facility
Cold chain management and
waste disposal
Cold  chain (at facility level)
Waste  management
Financing and
sustainability
Affordability Operational costs (although lack of monitoring) Outbreak costs reduced
(Mali  Men  A)
Reduced  revenues at
facility (Mali Men  A)
Domestic ﬁnancing Domestic ﬁnancing
increased
Sustainability concerns
External ﬁnancing External ﬁnancing
increased
Leadership/governance Regulatory policy Regulatory policy (all countries except in Mali
and Kenya)
Pharmacy and Poisons
Board  (in Kenya only)
Regulatory  policy (in
Mali  only)
Political commitment Reinforced EPI support
Organisation, structure, reform,
negotiation, stewardship
Planning
Inter-agency  Coordinating Committees (except
paign
Collaboration  enhanced (at
national level)
3
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p
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sfor Ethiopia and cam
introductions)
.2. Positive effects
New  vaccine introductions were seen as intrinsically positive, to
uch an extent that some study participants felt that their addition
er se strengthened the health system in a general sense.
“I think any new antigen reinforces [the] routine vaccination
programme because mothers know their children are better
protected.”M016,  national-level interviewee, Mali (PCV)
Respondents felt that the new vaccines would lead to a reduc-
ion in disease and would increase the public’s trust in the health
ystem.-based
3.2.1. Training
Staff  training in preparation for the introductions was  viewed
overwhelmingly positively. Some participants explained that it
acted as a refresher, allowing staff to update their vaccination skills,
e.g. cold chain management, as well as informing them about the
new vaccine.
3.2.2. Disease surveillance and AEFIs
There was generally no impact on disease surveillance systemsoverall. However in some countries positive effects were reported,
namely Cameroon, Mali and Kenya, where surveillance staff capac-
ity had reportedly been enhanced. In addition, in Mali (Men A)
case-based surveillance of meningitis was  introduced. This overall
6510 H.E.D. Burchett et al. / Vaccine 32 (2014) 6505–6512
Months
Fig. 1. Number of children vaccinated with Pentavalent 1 per month, before and after the introduction of a new routine vaccine$.
$Only countries introducing the new vaccine into their routine immunisation schedule i.e. Cameroon, Ethiopia, Guatemala, Kenya. Mali (PCV).
* a for 1
N uced i
l
o
t
uBecause of the phased introduction of the PCV13 in Mali, we could only collect dat
ote:  the vertical green dotted line shows the date that the new vaccine was  introdack of impact may  be because the development and strengthening
f surveillance systems was part of broader developments within
he health system and as such, were not tied speciﬁcally to individ-
al vaccine introductions.0 months post introduction in 13 health facilities.
nto the facility.Study participants felt that the effect of the new vaccine
introductions on adverse events following immunisation (AEFI)
reporting was  positive, though limited. In Ethiopia and Mali, the
AEFI surveillance systems had been strengthened, with training
accine
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nd speciﬁc communication for health workers on how to identify
nd respond to AEFIs for the new vaccine and the strengthening
f national and regional committees for surveillance of AEFIs. In
everal countries (particularly Kenya, Ethiopia and Mali for Men
) a lot of attention was  placed on creating awareness of potential
EFIs. These countries introduced vaccines with particular safety
oncerns; Kenya was the ﬁrst GAVI-eligible country to introduce
he preservative-free PCV10 vaccine, shortly followed by Ethiopia,
hilst Mali introduced a completely new Men  A vaccine [21].
However  despite overwhelming reports of enhanced awareness
f AEFIs, this did not lead to a change in the number of AEFIs
eported by health facilities, for any vaccine.
.2.3. Financing
The  impact of the new vaccines on domestic and external ﬁnan-
ing was viewed positively. Domestic funding for vaccines was
ncreased, albeit only for GAVI co-ﬁnancing in most cases; opera-
ional funds were generally reported to have remained unchanged.
ome interviewees believed that GAVI co-ﬁnancing encouraged a
ense of national ownership although concerns were also expressed
egarding ﬁnancial sustainability. It was also felt that the new vac-
ines provided access to additional external ﬁnancing; some key
nformants explained that the GAVI funding spurred others to offer
dditional support (e.g. for cold chain expansion).
.2.4. Organisation, structure, reform, negotiation and
tewardship: collaboration
There  were only changes in collaborations in a few spe-
iﬁc cases, where the new vaccine introduction led to new or
trengthened collaborations. For example, in Rwanda new collab-
rative links were made with the Ministry of Education due to
he school-based delivery strategy. In Kenya, multi-sector work-
ng had been established for previous vaccine introductions and
ad continued for this latest one, but there were also reports of
ew or improved links with the departments of health promo-
ion and HIV. In Mali the preparatory work for Men A increased
ollaboration between the agency for social mobilisation, the
inistry of Health and the National Institute for Infectious Dis-
ases.
.3. Negative effects
There  were few negative impacts reported and these were often
nly felt to occur in the short term, immediately after the introduc-
ion.
.3.1. Availability and distribution of staff: workload
The majority of health facility respondents (61%) reported that
orkload had increased at the time of, or just after, the new vac-
ine introduction. The effect on workload seemed to vary between
ountries; a perceived increase in workload was more common
n Kenya than Guatemala or Ethiopia. Some explained that the
ncrease was only temporary, perhaps caused by catch-up strate-
ies, returning to normal levels after a few months.
.3.2. Stock management: stock outs
Stock outs of the new vaccine were experienced in all the
routine introduction’ case studies (i.e. where the new vac-
ine was integrated into routine infant immunisation services,
s opposed to case studies where the new vaccine was  deliv-
red via campaigns), although they were more common in some
han others (e.g. in Kenya, 51% of facilities reported stock outs
ompared to 8% in Ethiopia). In many cases stock outs were
eported to be particularly notable in the ﬁrst few months after
ntroductions, when either demand exceeded expectations or a 32 (2014) 6505–6512 6511
catch-up strategy had not been incorporated into forecasting pre-
dictions.
Stock outs of other vaccines were also reported, but were rarely
associated with the new vaccine because they had occurred before
the introduction as well.
Stock outs had broader implications than just access to the new
vaccine; interviewees and facility staff explained that when one
vaccine was  out of stock, the public perceived there to be a generic
vaccine stock out and so stayed away from immunisation services
even if the speciﬁc vaccine that they required was available.
“So when it [the new PCV vaccine] is out of stock, it will affect
the  other vaccines which are available because the common per-
son  will just say, ‘The vaccine is not there.’ Then even the other
[person]  who  was supposed to get the other [vaccine] which is
available will not come.”
K022, regional-level interviewee, Kenya
3.4.  Differences between routine EPI and campaign-based
introductions
Unlike the other case studies, no stock-outs of the new vaccines
were reported in either country. This may  be because their deliv-
ery and logistics systems were separate from routine services, or
because they were required only for a limited period of time.
In  Rwanda, since the vaccine brought the immunisation
service to a completely new target population and delivery mode
(school-based), the opportunity was  taken to co-deliver various
interventions alongside the HPV vaccine, such as health promotion
sessions and de-worming treatment.
In Mali it was reported that there had been no more Men
A outbreaks since the new vaccine introduction. This meant
that expensive reactive campaigns were avoided. However, the
campaign disrupted routine services, which had the perceived
knock-on effect of reducing facilities’ revenues from those services.
Although the new vaccine campaigns ran for a limited time only, in
the Malian context where there are frequent short-term campaigns,
these routine service interruptions could add up to considerable
regular disruption [22].
Overall, both beneﬁts and drawbacks of campaign-delivered
introductions  seemed to be limited to the duration of the cam-
paigns.
4. Discussion
As far as the authors are aware, this is the ﬁrst study to focus
speciﬁcally on the impact of new vaccine introductions on the
broader health system in low- and middle-income countries. Our
study found that the new vaccines generally integrated well and as
such, had little or no impact on most aspects of the EPI and even
less on the broader health system. Effects outside of EPI were min-
imal or limited to a few cases where a deliberate effort was made
to combine activities.
Our  ﬁndings showed that there were limited inter-departmental
collaborations during introduction planning and this may  explain
why the impacts were more narrowly circumscribed to immunisa-
tion.
Perhaps the most surprising ﬁnding was  the lack of impact on
coverage rates for other vaccines (apart from a transient effect for
PCV13 in Mali) and the discord between this ﬁnding (from the
routine data) and the perceived increase reported by interviewees
and facility respondents. Some studies have reported a perceived
increase in health service use following the introduction of services
or new vaccines [3,16], however, others found no change [6,12].
Our results suggest that ﬁndings based on perceptions of increased
service use should be treated with caution.
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The ﬁnding that the introduction of an additional vaccine did
ot have many negative impacts, particularly for components such
s the cold chain capacity (except in Guatemala, where planning
as minimal), is a testament to the value of introduction prepara-
ions. It has been shown elsewhere that vial size affects supply chain
equirements and vaccine availability [23] and there is recognition
f the general need for additional cold chain for new vaccine intro-
uctions [11,24,25]. It should not be forgotten that health systems
re dynamic; fortuitous changes in the presentation of other vac-
ines as well as other concurrent initiatives (e.g. increasing stafﬁng)
s reported in this study, cannot be relied upon for future vaccine
ntroductions.
.1. Limitations
This study was conducted in seven countries only and focused
n ﬁve new vaccines. The effect of introductions will vary
epending on the nature of the new vaccine and its delivery, the
egree of preparation undertaken and the context of the EPI and
roader health system [4]. These ﬁndings may  therefore not be
eneralisable to all introductions in all settings. Nevertheless, they
ighlight key issues that may  be relevant to those introducing new
accines in low- and middle-income countries.
The inherently positive perception of new vaccines may  have
ade it difﬁcult for respondents to report negative impacts. The
ertical nature of EPI meant that many interviewees found it
ifﬁcult to respond to questions about the broader health sys-
em; conversely those outside of EPI often had little knowledge
bout new vaccine introductions. In some case studies the planned
ntroduction was delayed, resulting in fewer months of post-
ntroduction data being available to the study team. Finally, in some
ases, particularly in Mali (PCV), routine health service use data
ere not available in all facilities.
. Conclusion
Although the new vaccine introductions studied were viewed
s intrinsically positive, there was no evidence that they had any
ajor impact, positive or negative, on the broader health system.
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